From innovation to commercialization

Willem de Laat

Managing Director

Life Sciences & Health

8 December 2010

From innovation to commercialization

Global biomedical trends

1 Trillion $ sales in 2014

150 billion $ patent expirations

Ongoing consolidation

75% diseases without cure

Healthy ageing

Strong R&D investment

• Ref.: Scrip News, April 2010

1. Roche - $8.7B2. Pfizer - $7.4B3. Novartis - $7.06B4. Johnson & Johnson - $6.66B5. Sanofi-Aventis - $6.25B6. GlaxoSmithKline -  $5.59B7. Merck - $5.58B8. Takeda Pharmaceuticals - $4.64B

9. AstraZeneca - $4.23B 10. Eli Lilly - $4.13B11. Bristol-Myers Squibb - $3.48B12. Boehringer Ingelheim - $3.03B13. Abbott Laboratories - $2.61B14. Daiichi Sankyo - $1.89B15. Astellas Pharma - $1.63B

Global R&D spending

Health-related life sciences: an important sector in the Dutch economy

Drugs

Diagnostics

Devices

Companies Revenues FTE

Other

Total

Source: EIM study for EZ [2006], Voorstel LSG [2006]Preliminary data Biotech Outlook 2011

430

390

75

935

40

12.0 bn

2.7 bn

0.6 bn

15.7 bn

0.4 bn

37,000

12,000

54,600

3,400

± 150 companies highly innovative

Update 2010: >200 companies highly innovative

3% of GDP

2,200

The Dutch life sciences and health innovation cluster builds upon a strong knowledge base

Excellent biobanks and ‘real life’ datainfrastructure

120 mile radius

Global players & very high

concentration of SMEs

Excellentuniversities

5 of the top 10 European biotech deals are with Dutch companies, with a total value exceeding USD 2 billion

But....the consolidation changing environment has impact on the Netherlands

Organon Solvay Crucell

Life Sciences & Health Innovation ProgramImproving the investment and innovation climate in the Dutch life sciences and health sector

Hier komt een screenshot van de homepage 7 dec

5000+ unique visitors/month

Database forsubsidies and funding

Benchmark study on clinical trial performance to map the competitive

position of the Netherlands

Bio International Convention, Chicago, 2010

BIOBIO--EEUROPEUROPE SSPRINGPRING

MARCH 14-16, 2011, MARCH 14-16, 2011, MILAN, ITALYMILAN, ITALY

Thomson Pharma

Biotech Outlook 2011 will be launched in Q1 next year

Improved cluster assessment method • Cluster size, output & investments• Context with major events• Comparison with international clusters

Cooperation with international academicinstitutes

Cooperation on methodology with Council of European BioRegions

Progress

Sector vision

300 downloads

“TOPGEBIED LIFE SCIENCES”We have to Build, Nurture and Promote it together

Health &

Wealth

FEN-PHEN CASE (Wyeth)

Primary Pulmonary Hypertension on anti-obesity drug62 deaths before label change (1994)First court case (Billiton, Texas) $20 million20,000 claims < 1 monthDiscovery / browser /20,000 emailsWyeths prior knowledge exposedFirst settlement $1 billionReservations in Liability reserve fund total $21 billionStockprice decreased 50%

www.lifescienceshealth.com